Semaglutide — Technical Research
11 technical analysis articles
Looking for a simpler overview? Read the plain-language guide for Semaglutide →
Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.
Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.
Highlighting the potential of GLP1-RA as an effective treatment for weight regain following bariatric surgery and discussing its implications for clinical practice.
Highlighting the groundbreaking potential of semaglutide in preventing major adverse cardiovascular events among patients with obesity and existing cardiovascular disease.
Highlighting the efficacy and safety profile of modern anti-obesity drugs, focusing on liraglutide, semaglutide, and tirzepatide.
Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.
Exploring the Adherence Challenges and Influencing Factors of GLP-1 Receptor Agonists Among Patients With Overweight or Obesity
Highlighting the gap between clinical trial outcomes and real-world effectiveness of GLP-1RAs for weight management.
Highlighting the risks associated with compounded GLP-1 receptor agonists and advocating for stringent safety standards.
Highlighting the safety and potential benefits of GLP-1 receptor agonists in managing type 2 diabetes patients with or at risk for acute pancreatitis.